What Is Geromedicine? Where the Science of Aging Actually Stands

For most of modern history, medicine has operated like a game of whack-a-mole.

When your blood pressure spikes, we prescribe a pill for hypertension. If your blood sugar rises years later, we treat prediabetes. If a tumor develops decades after that, we refer you to oncology. We treat diseases as isolated, inevitable events that happen to pop up as we get older.

Geromedicine flips this entire model on its head.

Instead of waiting for individual age-related diseases to manifest one by one, geromedicine focuses on the single greatest risk factor for almost every chronic illness in existence: the biological aging process itself.

Here is a clear, evidence-based guide to what geromedicine actually is, why studying aging in humans is so difficult, and where the clinical science currently stands.

The Geroscience Hypothesis: Treating the Root Cause

To understand geromedicine, you first have to understand geroscience—the scientific field that studies the biological mechanisms driving aging.

At the heart of this field is the Geroscience Hypothesis [1]. The premise is simple: age is the primary driver behind heart disease, cancer, Alzheimer’s, type 2 diabetes, and osteoarthritis. Therefore, if we can understand and slow down the fundamental biological drivers of aging, we can delay or prevent multiple chronic diseases simultaneously.

Scientists have categorized these underlying biological drivers into the Hallmarks of Aging [1]. These interconnected processes include:

• Cellular Senescence: "Zombie cells" that stop dividing but refuse to die, secreting inflammatory signals that damage surrounding tissue.

• Genomic Instability & Epigenetic Alterations: Accumulated DNA damage and unwanted changes in how our genes are turned on or off over time.

• Mitochondrial Dysfunction & Loss of Proteostasis: The breakdown of cellular power plants and the accumulation of damaged proteins.

• Nutrient-Sensing Dysregulation: Disruptions in how cells process nutrients (involving metabolic pathways like mTOR and AMPK).

• Stem Cell Exhaustion & Altered Communication: The decline in tissue repair capacity and chronic systemic inflammation.

While geroscience studies these mechanisms in laboratories, geromedicine is the clinical application—translating these biological discoveries into practical, safe patient care.

Why Translating Geroscience to Humans Is So Difficult

It is relatively easy to slow down aging in a laboratory. Scientists have repeatedly extended the lifespans of roundworms, fruit flies, and mice using genetic tweaks, dietary changes, and specialized compounds.

Translating those laboratory breakthroughs to human patients, however, is notoriously difficult for a few major reasons:

1. Humans Live a Long Time: A laboratory mouse lives about 2 to 3 years, making lifespan trials fast and straightforward. A similar lifespan trial in humans would take 40 to 50 years, making human longevity trials practically impossible to run.

2. "Aging" Is Not Classified as a Disease: Regulatory agencies like the FDA do not recognize biological aging as an official disease state. Because of this, pharmaceutical companies cannot easily run clinical trials or get medications approved with "slowing aging" as the official target.

3. Mice Are Not Humans: Lab mice live in sterile, temperature-controlled environments, eat identical diets, and lack genetic diversity. Human lives are infinitely more complex, meaning what works in a genetically identical mouse often fails in human clinical trials.

A great example of this translational gap is the landmark CALERIE trial [2]. Researchers wanted to see if caloric restriction slowed aging in humans. While participants struggled to hit the target 25% caloric reduction—achieving an average of about 12%—they still showed remarkable improvements in blood pressure, cholesterol, and inflammation [2]. It proved that biological pathways respond in humans, but execution in real life is vastly different from a controlled lab cage.

The Unfiltered Truth: Nothing Is Proven to "Reverse" Aging in Humans

Because of these translational challenges, it is vital to be clear about where clinical medicine stands today: No pill, drug, supplement, or protocol has been proven in human clinical trials to slow or reverse the fundamental human aging process.

Anyone promising a guaranteed "anti-aging cure" or selling a supplement stack to "reverse your biological age" is selling marketing, not clinical science.

However, that does not mean all interventions are equal. Some candidates show far more translational promise than others.

Evaluating Candidate Gerotherapeutics: From Benchmark to Hype

To help patients separate real clinical evidence from online marketing, we map candidate aging interventions against a clinical evidence framework. You can explore the full breakdown in our free Gerotherapeutics Registry, but here is how the most common candidates actually stack up across the evidence spectrum:

1. The Clinically Validated Benchmark (Tier S)

• Caloric Restriction: In animal models, reducing caloric intake without malnutrition is the most consistent intervention for extending lifespan. In humans, trials like CALERIE prove that even modest caloric reduction significantly improves cardiometabolic risk factors and health trajectories [2].

2. Strong Translational Signals (Tier A & B)

• GLP-1s & SGLT-2 Inhibitors: Designed for diabetes and metabolic health, these medications show strong, replicated reductions in cardiovascular mortality and chronic disease in large human trials [3]. While some benefits stem from weight loss and blood sugar control, preclinical data suggests they also directly reduce oxidative stress and cellular inflammation [3].

• Rapamycin: Rapamycin inhibits mTOR, a master regulator of cellular growth and nutrient sensing. It is the gold-standard compound in preclinical geroscience, consistently extending lifespan across multiple animal species in the National Institute on Aging’s Interventions Testing Program (ITP) [4]. Early human trials show it can improve immune response in older adults, though long-term human lifespan data is still being evaluated [1,4].

3. Speculative Candidates (Tier C)

• Metformin: Metformin has been used for decades to treat type 2 diabetes, and observational data suggested diabetics taking metformin lived longer than expected. However, preclinical trials in healthy animals have been mixed—metformin alone failed to extend lifespan in non-diabetic mice in the ITP (though it did show benefits when combined with rapamycin) [4]. The upcoming TAME (Targeting Aging with Metformin) trial will help clarify if it protects non-diabetic humans, but for now, its role in healthy adults remains speculative.

4. Insufficient or Refuted (Tier D & F)

• NAD+ Boosters (NMN, NR): Heavily marketed on podcasts for cellular energy, a recent systematic review of 33 human studies confirmed that while these supplements raise NAD+ levels in the blood, their effects on actual physical strength, metabolic health, or hard clinical outcomes in humans are largely null or inconsistent [5].

• Senolytics (Dasatinib + Quercetin, Fisetin): Clearing "zombie" senescent cells shows impressive results in mice, but translating these drugs to humans is still in very early, unproven stages.

• Resveratrol: Once touted as the ultimate longevity molecule, resveratrol failed to extend lifespan in rigorous, replicated animal studies conducted by the NIA ITP and has consistently failed to show meaningful clinical benefit in human trials [4].

The Bottom Line

Geromedicine represents an exciting shift in how we think about health. By moving away from reactive disease management toward proactive, foundational prevention, we can help people stay healthier and more functional for longer.

However, protecting your healthspan doesn't require chasing unproven trends or buying into gray-market hype. Real, evidence-based geromedicine focuses on what we can prove today: optimizing physical fitness, applying targeted cardiovascular and metabolic prevention, using validated medical therapies when appropriate, and building a clear, long-term strategy that protects your health for decades to come.

References

1. Kritchevsky SB, Cummings SR. Geroscience. JAMA. 2025;334(12):1094-1102.

2. Kraus WE, Bhapkar M, Huffman KM, et al. 2-Year Calorie Restriction and Cardiometabolic Risk (CALERIE): Exploratory Outcomes of a Multicentre, Phase 2, Randomised Controlled Trial. The Lancet Diabetes & Endocrinology. 2019;7(9):673-683.

3. Forman DE, Kuchel GA, Newman JC, et al. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Journal of the American College of Cardiology. 2023;82(7):631-647.

4. Miller RA, Harrison DE, Astle CM, et al. Rapamycin, But Not Resveratrol or Metformin, Extends Lifespan in Genetically Heterogeneous Mice. The Journals of Gerontology: Series A. 2011;66A(2):191-201.

5. Gallagher C, Emmanuel OO. NAD⁺ Supplementation for Anti-Aging and Wellness: A PRISMA-guided Systematic Review of Preclinical and Clinical Evidence. Ageing Research Reviews. 2026;116:103057.